Xarelto (rivaroxaban) is an oral blood thinner used to prevent stroke by reducing the body's ability to form blood clots in patients with atrial fibrillation or recovering from hip and knee replacement surgeries. It has been linked to severe, uncontrolled internal bleeding, sometimes resulting in death, in some users. Xarelto is the second anti-coagulant drug that has been at the center of a multitude of a lawsuits involving internal bleeding allegations. The first was Pradaxa, produced and marketed by Boehringer Ingelheim, which agreed to pay $650 million to settle roughly 2,300 lawsuits in 2014. Janssen Pharmaceuticals, which makes Xarelto, now faces similar allegations in a Multi-District Litigation.
Xarelto lawsuits were consolidated in December of 2014 in Louisiana as the Xarelto Products Liability Litigation, MDL No. 2592. The efforts of trial lawyers to attract Xarelto bleeding clients has been intensified by the success of the Pradaxa litigation.
247LawsuitNews.com expects significant ongoing activity and will update this section frequently as Xarelto Products Liability Litigation unfolds.